Table 3.
Medications associated with thrombotic microangiopathy
| Antineoplastic agents |
| Antiangiogenesis drugs |
| Mitomycin-C |
| Gemcitabine |
| Cisplatin/carboplatin |
| Estramustine/lomustine |
| Cytarabine |
| Tamoxifen |
| Bleomycin |
| Daunorubicin |
| Hydroxyurea |
| Antiplatelet agents |
| Ticlopidine, clopidogrel, prasugrel |
| Dipyradamole |
| Defribrotide |
| IFNs |
| IFN-α and -β |
| Immunosuppressive agents |
| Calcineurin inhibitors |
| Anti-CD33 (OKT3) |
| Antimicrobial agents |
| Valacyclovir |
| Penicillins |
| Rifampin |
| Metronidazole |
| Tetracycline |
| Sulfasoxazole |
| Albendazole |
| Nonsteroidal anti–inflammatory drugs |
| Diclofenac |
| Piroxicam |
| Ketorolac |
| Hormones |
| Conjugated estrogens alone or combined with progestins |
| Contraceptives, combination |
| Others |
| Quinine |
| Intravenous oxymorphone (Opana) ER |
| Simvastatin |
| Iodine |
| Cocaine |
ER, extended release.